

June 5, 2023

**skye**Bioscience

# Skye Bioscience to Present at LD Micro Invitational XIII

San Diego, California--(Newsfile Corp. - June 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, will be presenting at the 13th Annual LD Micro Invitational being held at the Luxe Sunset Boulevard Hotel, California June 6th-8th, 2023. The Company will also be available for 1:1 meetings.

Punit Dhillon, CEO and Chair, will provide a corporate overview of Skye in his presentation on Wednesday, June 7, at 2:30 PM PT.

We invite interested parties to register to watch the presentation virtually [here](https://ldinv13.sequireevents.com/):  
<https://ldinv13.sequireevents.com/>.

## About SBI-100 Ophthalmic Emulsion

Skye's SBI-100 OE possesses a novel molecular structure and nanoemulsion formulation that were designed to enable effective topical delivery and better penetration of a CB1R agonist into ocular tissue. In preclinical studies involving three different species, the drug resulted in enhanced therapeutic efficacy and duration of response in lowering IOP, comparing favorably to the standard of care for treating glaucoma. Skye expects to complete dosing of the final cohort of its Phase 1 study of SBI-100 OE in June and report data in the third quarter of 2023. In the first five treatment cohorts there were no serious adverse events and mild to moderate drug-related adverse events that are typically associated with topical eye treatments. Skye is concurrently preparing to start a Phase 2 study mid-year 2023.

## About Skye Bioscience

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The Company's lead program, SBI-100 OE, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness. For more information, please visit: [www.skyebioscience.com](http://www.skyebioscience.com).

## About LD Micro

LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit [www.ldmicro.com](http://www.ldmicro.com).

To present or register, please get in touch with [Dean@ldmicro.com](mailto:Dean@ldmicro.com)

To learn more about Freedom US Markets, visit [www.freedomusmkt.com](http://www.freedomusmkt.com)

## **CONTACT**

Investor Relations

Email: [ir@skyebioscience.com](mailto:ir@skyebioscience.com)

Phone: (858) 410-0266

## **FORWARD LOOKING STATEMENTS**

This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.



To view the source version of this press release, please visit

<https://www.newsfilecorp.com/release/168743>

SOURCE Skye Bioscience, Inc.